Dr Krueger was born and raised in a ranching community it North Dakota. Following a BA degree in chemistry from Union College, Dr. Krueger obtained his MD degree from Loma Linda University School of Medicine in 1966. Following internship in the military and the residency at the University of Colorado, Dr. Krueger was recruited to the University of Utah where he started the Division of Dermatology, later to become the Department of Dermatology. His research career research spreads across investigative dermatology, he holds a patent on the human-rat skin flap, human skin supported by a the rats vasculature and their mammalian nutritional support. This led to his thorough understanding of the challenges of absorption of topically applied agents as well as delivery of systemic agents into human skin on the human-rat flap. He was principal investigator of a NIH funded program project for 10 years which was directed at the feasibility using genetically modified skin to correct genetic diseases of the skin and to deliver molecules from therapeutic genes placed into skin to the systemic circulation. His deepest interest is in psoriasis, this started in 1972 when he realized he could study both diseased and normal appearing skin from patients transplanted to athymic mice. For over 40 years he also has been the principal investigator on over 100 clinical trials on psoriasis and has done basic research on psoriasis with NIH support for over 25 years. Dr. Krueger has published over 250 papers in the medial literature, mostly on psoriasis. He served as the chairman of the Medical Advisory Board of the National Psoriasis Foundation (1993 to 2003); serves as a U S Councilor to the International Psoriasis Council, was an organizer and then officer of psoriatic arthritis interest group, (GRAPPA) for over 10 years. In summary, his research has ranged from drug distribution into and out of human skin, to gene therapy via human skin to his current focus, understanding the relationship of genotype to phenotype using psoriasis as a model disease via the Utah Psoriasis Initiative (UPI).